Infliximab biosimilar use in Crohn's disease will boost the market and help patients, says report

16 March 2018

New clinical data will support the use of a biosimilar treatment for Crohn’s disease (CD), and lead to a boost in biosimilar market value, a new report suggests.

In February 2018, 12-month data from the Personalized Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organization (ECCO). The highly anticipated results demonstrated that Celltrion’s (Kosdaq: 068270) CT-P13 (infliximab biosimilar) is comparable to its reference, Johnson & Johnson’s (NYSE: JNJ) Remicade (infliximab), as well as AbbVie’s (NYSE: ABBV) Humira (adalimumab), according to analytics company GlobalData.

Lakshmi Dharmarajan, associate director of immunology at GlobalData, comments: “Given the dearth of head-to-head trial data, this is expected to bolster the use of biosimilars, and lead to cost-effective treatment strategies for patients with CD.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK